BALA CYNWYD, Pa., April 25, 2013 /PRNewswire/ -- Law office of
Brodsky & Smith, LLC announces that it is investigating
potential claims against the Board of Directors of PROLOR Biotech,
Inc. ("PROLOR" or the "Company") (NYSE- PBTH) relating to the
proposed acquisition by OPKO Health, Inc. ("OPKO").
Under the terms of the transaction, PROLOR shareholders will
receive only 0.9951 shares of OPKO stock for each share of PROLOR
stock they own. The transaction values PROLOR stock at
approximately $7.025 per share. The
investigation concerns possible breaches of fiduciary duty and
other violations of state law by the Board of Directors of PROLOR
for not acting in the Company's shareholders' best interests in
connection with the sale process. The transaction may undervalue
the Company as an analyst has set a $12.00 per share price target on PROLOR stock. In
addition, it has been reported that Deerpath Capital has indicated
that the Company is worth more than $10.00 per share.
If you own shares of PROLOR stock and wish to discuss the legal
ramifications of the proposed transaction, or have any questions,
you may e-mail or call the law office of Brodsky & Smith, LLC
who will, without obligation or cost to you, attempt to answer your
questions. You may contact Jason L.
Brodsky, Esquire or Evan J. Smith,
Esquire at Brodsky & Smith, LLC, Two Bala Plaza, Suite
602, Bala Cynwyd, PA 19004, by
e-mail at investorrelations@brodsky-smith.com visiting
http://brodsky-smith.com/571-pbth-prolor-biotech-inc.html, by
calling toll free 877-LEGAL-90.
Attorney advertising. Prior results do not guarantee a similar
outcome.
SOURCE Brodsky & Smith, LLC